Fig. 5From: Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacya–g Structure comparison of Bcr-Abl preclinically validated inhibitors. Chemical structures are here represented in color code with regard to analogous groups of different tyrosine kinase inhibitors (green: core structure; red and blue: substituents group)Back to article page